[go: up one dir, main page]

NO20071547L - Nye krystallinske og amorfe former av en triazolo(4,5-D)pyrimidinforbindelse - Google Patents

Nye krystallinske og amorfe former av en triazolo(4,5-D)pyrimidinforbindelse

Info

Publication number
NO20071547L
NO20071547L NO20071547A NO20071547A NO20071547L NO 20071547 L NO20071547 L NO 20071547L NO 20071547 A NO20071547 A NO 20071547A NO 20071547 A NO20071547 A NO 20071547A NO 20071547 L NO20071547 L NO 20071547L
Authority
NO
Norway
Prior art keywords
amorphous forms
triazolo
pyrimidine compound
new crystalline
novel compounds
Prior art date
Application number
NO20071547A
Other languages
English (en)
Other versions
NO332306B1 (no
Inventor
Martin Bohlin
Steve Cosgrove
Bo Lassen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9892841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20071547(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO20071547L publication Critical patent/NO20071547L/no
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO332306B1 publication Critical patent/NO332306B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Oppfinnelsen angår nye krystallinske og amorfe former av en kjemisk forbindelse med formel (I), fremgangsmåte for fremstilling av slike samt ulike anvendelser av de nevnte nye forbindelser. Videre angår oppfinnelsen farmasøytiske preparat omfattende nevnte nye forbindelser.
NO20071547A 2000-06-02 2007-03-23 Nye krystallinske former av en triazolo(4,5-D)pyrimidinforbindelse, fremgangsmate for fremstilling derav, anvendelse derav samt farmasoytisk sammensetning NO332306B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0013407.2A GB0013407D0 (en) 2000-06-02 2000-06-02 Forms of a chemical compound
PCT/SE2001/001239 WO2001092262A1 (en) 2000-06-02 2001-05-31 New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound

Publications (2)

Publication Number Publication Date
NO20071547L true NO20071547L (no) 2003-01-24
NO332306B1 NO332306B1 (no) 2012-08-20

Family

ID=9892841

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20025756A NO323780B1 (no) 2000-06-02 2002-11-29 Nye krystallinske former av en triazolo(4,5-D)pyrimidinforbindelse, fremgangsmate for fremstilling og anvendelser av slike samt farmasoytisk preparat inneholdende nevnte nye forbindelser.
NO20071547A NO332306B1 (no) 2000-06-02 2007-03-23 Nye krystallinske former av en triazolo(4,5-D)pyrimidinforbindelse, fremgangsmate for fremstilling derav, anvendelse derav samt farmasoytisk sammensetning
NO20120595A NO333289B1 (no) 2000-06-02 2012-05-14 Blanding av vesentlig krystallinske former av en triazolo(4,5-D)pyrimidinforbindelse, farmasoytisk sammensetning samt anvendelser derav

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20025756A NO323780B1 (no) 2000-06-02 2002-11-29 Nye krystallinske former av en triazolo(4,5-D)pyrimidinforbindelse, fremgangsmate for fremstilling og anvendelser av slike samt farmasoytisk preparat inneholdende nevnte nye forbindelser.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20120595A NO333289B1 (no) 2000-06-02 2012-05-14 Blanding av vesentlig krystallinske former av en triazolo(4,5-D)pyrimidinforbindelse, farmasoytisk sammensetning samt anvendelser derav

Country Status (36)

Country Link
US (3) US20030181469A1 (no)
EP (3) EP1289992B1 (no)
JP (3) JP5036947B2 (no)
KR (1) KR100781864B1 (no)
CN (2) CN1247583C (no)
AR (2) AR032335A1 (no)
AT (2) ATE555115T1 (no)
AU (4) AU6287401A (no)
BG (3) BG65837B1 (no)
BR (1) BR0111328A (no)
CA (1) CA2408596C (no)
CY (1) CY1113047T1 (no)
CZ (2) CZ304347B6 (no)
DE (1) DE60117972T2 (no)
DK (2) DK1493745T3 (no)
EE (1) EE05222B1 (no)
ES (2) ES2259031T3 (no)
GB (1) GB0013407D0 (no)
HK (1) HK1052347B (no)
HU (2) HU229374B1 (no)
IL (4) IL152777A0 (no)
IS (2) IS2609B (no)
MX (1) MXPA02011795A (no)
MY (2) MY140674A (no)
NO (3) NO323780B1 (no)
NZ (1) NZ522638A (no)
PH (1) PH12011000127A1 (no)
PL (2) PL392882A1 (no)
PT (2) PT1289992E (no)
RU (3) RU2325391C2 (no)
SG (1) SG135965A1 (no)
SI (2) SI1493745T1 (no)
SK (1) SK287817B6 (no)
UA (1) UA73181C2 (no)
WO (1) WO2001092262A1 (no)
ZA (1) ZA200209324B (no)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
GB0013488D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
GB0013407D0 (en) 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
JP4298212B2 (ja) * 2002-03-29 2009-07-15 大日本印刷株式会社 塩酸エピナスチン高融点型結晶の製造法
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
US20080045548A1 (en) * 2006-08-21 2008-02-21 Astrazeneca Ab Pharmaceutical Compositions
WO2008054795A2 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica, N.V. Triazolopyrimidine derivatives as adp p2y12 receptor antagonists
KR101473207B1 (ko) * 2007-04-13 2014-12-16 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｘａ 인자 억제제로서 작용하는 화합물과의 병용 항응고 요법
TWI496776B (zh) * 2007-11-15 2015-08-21 Astrazeneca Ab 製備(3aR,4S,6R,6aS)-6-胺基-2,2-二甲基四氫-3aH-環戊并[d][1,3]二氧雜環戊烯-4-醇之純非對映異構性之二苯甲醯-L-酒石酸鹽之方法
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
RU2509082C2 (ru) 2008-09-09 2014-03-10 Астразенека Аб СПОСОБ ПОЛУЧЕНИЯ [1S-[1α,2α,3β(1S*,2R*),5β]]-3-[7-[2-(3,4-ДИФТОРФЕНИЛ)-ЦИКЛОПРОПИЛАМИНО]-5-(ПРОПИЛТИО)-3H-1,2,3-ТРИАЗОЛО[4,5-d]ПИРИМИДИН-3-ИЛ]-5-(2-ГИДРОКСИЭТОКСИ)-ЦИКЛОПЕНТАН-1,2-ДИОЛА И ЕГО ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ
EP3135675A1 (en) 2009-07-27 2017-03-01 Auspex Pharmaceuticals, Inc. Deuterated derivatives of ticagrelor for medical use
JP2013512886A (ja) * 2009-12-03 2013-04-18 アストラゼネカ アクチボラグ 血小板の凝集阻害剤トリアゾロ［４，５−ｄ］ピリミジン共結晶
US8663661B2 (en) 2009-12-23 2014-03-04 Ratiopharm Gmbh Solid pharmaceutical dosage form of ticagrelor
CZ2011229A3 (cs) * 2011-04-19 2012-08-15 Zentiva, K.S. Opticky aktivní soli (3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyklopenta-[d][1,3]dioxol-4-olu a zpusob jejich prípravy
RU2013154741A (ru) 2011-06-01 2015-07-20 Астразенека Аб Новый сокристалл тикагрелора
WO2013079589A1 (en) * 2011-11-30 2013-06-06 Actavis Group Ptc Ehf Novel crystalline form of ticagrelor and process for the preparation thereof
US9233966B2 (en) 2012-04-05 2016-01-12 Dr. Reddy's Laboratories Limited Preparation of ticagrelor
WO2014000719A1 (en) 2012-06-29 2014-01-03 Zentiva, K.S. Novel pharmaceutical solid forms of (1s,2s,3r,5s)-3-[7-[(1r,2s)-2-(3,4difluorophenyl)cyclopropylamino]-5-(propylthio)-3h-[1,2,3]triazolo[4,5-d]pyrimidin-3yl]-5-(2-hydroxyethoxy)cyclopentane-l,2-diol
WO2014006091A1 (en) 2012-07-04 2014-01-09 Lek Pharmaceuticals D.D. Ticagrelor adducts with divalent metal salts
CZ2012705A3 (cs) * 2012-10-16 2014-04-23 Zentiva, K.S. Pevná orální farmaceutická formulace obsahující ticagrelor
CN103772393B (zh) * 2012-10-18 2017-08-04 博瑞生物医药（苏州）股份有限公司 替卡格雷的晶型及其制备方法
WO2014083139A1 (en) * 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Novel amorphous form of ticagrelor
CN103848836B (zh) * 2012-12-07 2016-08-03 天津市汉康医药生物技术有限公司 替卡格雷倍半水合物及其制备方法
WO2014118808A2 (en) * 2013-02-04 2014-08-07 Hetero Research Foundation Ticagrelor solid dispersion
CZ307217B6 (cs) 2013-03-14 2018-04-04 Zentiva, K.S. Zlepšený způsob výroby a nové intermediáty syntézy ticagreloru
IN2013MU01111A (no) * 2013-03-25 2015-05-01 Glenmark Generics Ltd
CN104098570A (zh) * 2013-04-07 2014-10-15 杭州领业医药科技有限公司 替卡格雷晶型及其制备方法和用途
CN104098572A (zh) * 2013-04-08 2014-10-15 博瑞生物医药技术(苏州)有限公司 替卡格雷共晶型
CN104098553B (zh) * 2013-04-10 2017-11-28 江苏恒瑞医药股份有限公司 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
EP2813216A1 (en) 2013-06-10 2014-12-17 Zentiva, a.s. Stabilized amorphous ticagrelor
WO2014170026A1 (en) 2013-04-18 2014-10-23 Zentiva, K.S. Stabilized amorphous ticagrelor
CA2913326A1 (en) 2013-05-29 2014-12-04 Ratiopharm Gmbh Solid pharmaceutical dosage form
CN106496234B (zh) * 2013-06-03 2019-08-30 杭州领业医药科技有限公司 结晶形态的三唑[4,5-d]嘧啶化合物及其制备方法和用途
WO2014195861A2 (en) * 2013-06-04 2014-12-11 Dr. Reddy’S Laboratories Limited Preparation of ticagrelor
EP2816043A1 (en) 2013-06-21 2014-12-24 LEK Pharmaceuticals d.d. Spherical ticagrelor particles
WO2015001489A1 (en) * 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Pharmaceutical compositions of ticagrelor
CN104341423B (zh) * 2013-08-02 2017-03-01 上海京新生物医药有限公司 替格瑞洛的一水合物及其制备方法与在制药中的应用
CN104370912A (zh) * 2013-08-13 2015-02-25 开原亨泰制药股份有限公司 替卡格雷多晶型体及其制备方法
WO2015037016A2 (en) * 2013-09-10 2015-03-19 Laurus Labs Private Limited An improved process for the preparation of ticagrelor and intermediates thereof
CZ2013866A3 (cs) 2013-11-08 2015-05-20 Zentiva, K.S. Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru
CN104650085A (zh) * 2013-11-22 2015-05-27 天津市汉康医药生物技术有限公司 替卡格雷倍半水合物化合物
CN103601726B (zh) * 2013-12-02 2016-09-28 浙江大学 两种替格瑞洛药物共晶及其制备方法
CN104710425B (zh) * 2013-12-16 2019-06-14 石药集团中奇制药技术（石家庄）有限公司 一种替格瑞洛新结晶及其制备方法
CN104650091B (zh) * 2014-01-24 2016-10-05 福州乾正药业有限公司 替格瑞洛的微粉化及其晶型，以及制备方法和药物应用
CN104940204A (zh) * 2014-03-27 2015-09-30 广东东阳光药业有限公司 一种替格瑞洛固体制剂及其制备方法
WO2015162537A1 (en) * 2014-04-23 2015-10-29 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of ticagrelor
WO2015162630A1 (en) 2014-04-25 2015-10-29 Anlon Chemical Research Organization Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis.
CN105315282B (zh) * 2014-07-15 2018-09-21 博瑞生物医药（苏州）股份有限公司 一种制备替卡格雷无定型的方法
WO2016016907A1 (en) * 2014-08-01 2016-02-04 Msn Laboratories Private Limited Novel polymorphs of (1s,2s,3r,5s)-3-[7-{[(1r,2s)-2-(3,4-difluorophenyl) cyclopropyl]amino}-5-(propylthio)-3h-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yi]-5-(2-hydroxvethoxy) cyclopentane-1,2-diol
WO2016024225A1 (en) * 2014-08-11 2016-02-18 Sun Pharmaceutical Industries Limited Stable amorphous ticagrelor and a process for its preparation
CN104193747B (zh) * 2014-08-12 2016-05-11 许彩霞 替卡格雷无定形的制备
WO2016116942A1 (en) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
CN105968113B (zh) * 2015-03-12 2019-06-07 四川海思科制药有限公司 一种三唑并嘧啶衍生物及其应用
WO2017072790A1 (en) * 2015-10-26 2017-05-04 Avra Laboratories Pvt. Ltd. An improved process for synthesis of ticagrelor
WO2017118633A1 (en) * 2016-01-05 2017-07-13 Amneal Pharmaceuticals Company Gmbh Crystalline form of ticagrelor
CN107595789B (zh) 2016-04-21 2021-01-15 阿斯利康(瑞典)有限公司 口腔崩解片
ES2731658T3 (es) * 2016-09-09 2019-11-18 Univ Liege Derivados triazolo(4,5-d)pirimidina para uso en la prevención y tratamiento de infección bacteriana
US10905691B2 (en) 2016-09-09 2021-02-02 Université de Liège Use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection
KR101916956B1 (ko) 2016-12-13 2018-11-08 보령제약 주식회사 티카그렐러의 신규한 고체 형태 및 이의 제조방법
WO2018178997A1 (en) 2017-03-31 2018-10-04 Natco Pharma Limited Novel crystalline form of ticagrelor
WO2019127294A1 (zh) * 2017-12-29 2019-07-04 浙江天宇药业股份有限公司 一种纯化替格瑞洛的方法
WO2019170244A1 (en) 2018-03-08 2019-09-12 Pharmaceutical Oriented Services Ltd. Ticagrelor—containing tablet formulation
WO2020021110A1 (en) 2018-07-27 2020-01-30 Krka, D.D., Novo Mesto Pharmaceutical composition of ticagrelor
CN110194771A (zh) * 2019-05-08 2019-09-03 北京济美堂医药研究有限公司 一种替格瑞洛药用ii晶型的制备方法
CN114634489B (zh) * 2022-04-19 2023-07-04 奎马特里克斯有限公司 结晶形式
CN117510508A (zh) * 2023-11-14 2024-02-06 江苏普润生物医药有限公司 一种高纯度ii晶型替格瑞洛的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
FR2687677B1 (fr) * 1992-02-24 1996-10-11 Union Pharma Scient Appl Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant.
KR100444123B1 (ko) * 1995-07-11 2004-10-14 아스트라제네카 악티에볼라그 신규한혈소판응집억제제
DE69710490T2 (de) * 1996-12-20 2002-10-24 Astrazeneca Ab, Soedertaelje Triazolo(4,5-d)pyrimidinyl-derivate und ihre verwendung als medikamente
TW530058B (en) 1997-07-22 2003-05-01 Astra Pharma Prod Triazolo [4,5-d]pyrimidine compounos and their use and process for preparation
WO1999005150A1 (en) * 1997-07-25 1999-02-04 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9904129D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
GB0013488D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound

Also Published As

Publication number Publication date
NO20025756L (no) 2003-01-24
CN1817883A (zh) 2006-08-16
IL152777A0 (en) 2003-06-24
AU2010257449A1 (en) 2011-01-20
IL152777A (en) 2008-11-26
EE05222B1 (et) 2009-10-15
HU229374B1 (en) 2013-11-28
NO20120595L (no) 2003-01-24
NO333289B1 (no) 2013-04-29
HK1073101A1 (en) 2005-09-23
DK1493745T3 (da) 2012-07-16
RU2418802C2 (ru) 2011-05-20
BG110440A (bg) 2010-03-31
CY1113047T1 (el) 2016-04-13
RU2010150799A (ru) 2012-06-20
SI1289992T1 (sl) 2006-08-31
EP1289992A1 (en) 2003-03-12
CN1247583C (zh) 2006-03-29
JP2012149093A (ja) 2012-08-09
BG65837B1 (bg) 2010-02-26
CZ20120293A3 (no) 2003-07-16
NO332306B1 (no) 2012-08-20
WO2001092262A1 (en) 2001-12-06
US20030181469A1 (en) 2003-09-25
AU2007200958A1 (en) 2007-03-29
BG111017A (bg) 2011-12-30
HUP0302284A3 (en) 2007-05-29
AR068086A2 (es) 2009-11-04
DE60117972D1 (de) 2006-05-11
EE200200665A (et) 2004-06-15
PT1493745E (pt) 2012-06-28
IS3019B (is) 2020-02-15
CN1432018A (zh) 2003-07-23
HK1052347B (en) 2006-09-08
IL187482A (en) 2010-06-16
JP2003535092A (ja) 2003-11-25
US20070173518A1 (en) 2007-07-26
AU6287401A (en) 2001-12-11
PH12011000127A1 (en) 2016-08-31
ZA200209324B (en) 2004-02-16
US20070293513A1 (en) 2007-12-20
NO20025756D0 (no) 2002-11-29
PL359172A1 (en) 2004-08-23
CZ304347B6 (cs) 2014-03-19
JP2014129423A (ja) 2014-07-10
DE60117972T2 (de) 2006-11-23
MXPA02011795A (es) 2003-04-10
ES2259031T3 (es) 2006-09-16
IS2609B (is) 2010-04-15
SI1493745T1 (sl) 2012-08-31
PL392882A1 (pl) 2011-03-14
RU2005127356A (ru) 2007-03-10
KR100781864B1 (ko) 2007-12-05
CN1817883B (zh) 2011-10-05
HU230471B1 (hu) 2016-07-28
AU2010257449B2 (en) 2012-03-22
MY148652A (en) 2013-05-15
EP1493745B2 (en) 2021-05-19
RU2325391C2 (ru) 2008-05-27
IL202582A0 (en) 2010-06-30
MY140674A (en) 2010-01-15
EP1493745A1 (en) 2005-01-05
IS8825A (is) 2009-06-02
ES2384708T3 (es) 2012-07-11
EP1493745B1 (en) 2012-04-25
UA73181C2 (en) 2005-06-15
HK1052347A1 (en) 2003-09-11
BR0111328A (pt) 2003-06-10
AU2007200958B2 (en) 2010-10-07
GB0013407D0 (en) 2000-07-26
CZ307468B6 (cs) 2018-09-26
JP5036947B2 (ja) 2012-09-26
NO323780B1 (no) 2007-07-02
IL202582A (en) 2012-12-31
BG66332B1 (bg) 2013-06-28
EP2292622A1 (en) 2011-03-09
AR032335A1 (es) 2003-11-05
SK16852002A3 (sk) 2003-08-05
DK1289992T3 (da) 2006-07-03
KR20030007829A (ko) 2003-01-23
NZ522638A (en) 2004-06-25
CA2408596C (en) 2010-12-21
SK287817B6 (sk) 2011-11-04
JP5684192B2 (ja) 2015-03-11
ATE320430T1 (de) 2006-04-15
BG107331A (bg) 2003-07-31
CA2408596A1 (en) 2001-12-06
PT1289992E (pt) 2006-07-31
US7265124B2 (en) 2007-09-04
HUP1300386A2 (en) 2003-10-28
AU2001262874B2 (en) 2007-03-22
EP1289992B1 (en) 2006-03-15
IS6623A (is) 2002-11-15
SG135965A1 (en) 2007-10-29
HUP0302284A2 (hu) 2003-10-28
ATE555115T1 (de) 2012-05-15

Similar Documents

Publication Publication Date Title
NO20071547L (no) Nye krystallinske og amorfe former av en triazolo(4,5-D)pyrimidinforbindelse
DE60131967D1 (de) Nr1h4-kern-rezeptor-bindende verbindungen
ATE293114T1 (de) Cephemverbindungen mit einem imidazo(4,5- b)pyridiniummethyl-rest, die ein breites antibakterielles wirkungsspektrum haben
WO2005092858A3 (en) Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
WO2005061458A3 (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
NO20004089L (no) Nye triazolo(4,5-d)pyrimidinforbindelser
NO20016389L (no) Fremgangsmåte for fremstilling av substituerte cyklopentanderivater og nye krystallinske strukturer derav
AU8811401A (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
CA2423286A1 (en) Amorphous form of cell cycle inhibitor
SE9802574D0 (sv) Novel compounds
WO2003080631A3 (en) Plasma carboxypeptidase b inhibitors
MY129094A (en) Condensed polycyclic compounds
CA2374643A1 (en) 1-trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives as substance p antagonists
WO2002059089A3 (en) Process for the preparation of heterocyclic indene analogs
WO2006134486A3 (en) Alpha-(aryl-or heteroaryl-methyl)-beta piperidino propanamide compounds as orl1-receptor antagonists
WO2001081298A3 (en) Cyclic carboxylic acids as integrin antagonists
ZA200300218B (en) Novel N-(2-phenyl-3-aminopropyl)naphtamides.
NO20031046D0 (no) Fremgangsmåte for fremstilling av en substituert imidazopyridinforbindelse
CA2392674A1 (en) Pyrazoloquinolinone derivatives as protein kinase c inhibitors
ATE345343T1 (de) Triazolo(4,5-d)pyrimidinderivate als antithrombotische verbindungen
NO20052197L (no) Fremgangsmate for fremstilling av pyrazol
NO20055755L (no) Nytt intermediat for fremstillingen av terapeutisk aktive imidazopyridiner
AU2319000A (en) Thiazolopyrimidine compounds, process for the preparation of the same and uses thereof
IT1317886B1 (it) Procedimento per la preparazione di 9,10-diidro-pirrolo (2,1-b)(1,3)benzotiazepine 9-ammino sostituite.
TH72865A (th) อนุพันธ์เบนโซอิล-ปิเปอราซีน

Legal Events

Date Code Title Description
MK1K Patent expired